RDNA-07. IDH1-MUTANT GLIOBLASTOMA (GBM) CELLS FROM A PATIENT POST-TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARE SENSITIVE TO TTFIELDS IN VITRO

BACKGROUND: Tumor treating fields (TTFields) are FDA-approved for treatment of newly-diagnosed and recurrent GBM. TTFields extend progression-free survival and overall survival. Despite this advancement in patient outcome, many patients undergoing TTFields treatment ultimately progress with tumor re...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Michelhaugh, Sharon, Kiousis, Sam, Klinger, Neil, Mittal, Sandeep
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217513/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.923
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares